Investment case
Teva Pharmaceutical Industries Ltd.
TEVA · 12 developments mapped · last assessed 2026-09-19
Market Ontology has mapped 12 macro, policy, and market developments to Teva Pharmaceutical Industries Ltd. since 2026-08-26. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for TEVA yet, so no modelled value is shown. The TEVA valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run TEVA on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity
Direct positive impact on UZEDY sales and market share due to demonstrated superior real-world outcomes, potentially leading to increased prescriptions and payer preference.
· Moves uzedy peak sales estimates, market share for long acting injectables in schizophrenia/bipolar i, future r&d allocation for similar real world evidence studies
- Open question
Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms
Potential for increased competition in neurological disorder treatments, or opportunities for late-stage development/commercialization partnerships.
· Moves market share assumptions, pipeline valuation
What changed, by assumption
- 2026-09-19Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity
- 2026-09-19Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions
- 2026-09-19Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables
- 2026-09-19Teva real-world data demonstrates UZEDY reduces emergency care and medical costs
- 2026-09-19Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity
- 2026-09-19Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilization
- 2026-09-07Teva Launches Multi-Currency Senior Notes to Refinance High-Coupon 2028-2029 Debt
- 2026-09-07Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 Debt
- 2026-09-19Teva presents real-world data showing UZEDY treatment continuity advantage
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-09-11 | Cost of capital | Bullish | Higher cost-of-debt tranche lifts blended WACC. | 0.70 |
| 2026-09-11 | Interest expense | Bullish | High-yield coupon materially raises interest burden. | 0.70 |
| 2026-09-11 | Net debt | Bullish | Sub-IG debt raise increases leverage and net debt. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-19 | Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity | Bullish | 1-3m | 0.80 |
| 2026-09-19 | Teva presents real-world data showing UZEDY treatment continuity advantage | Bullish | 1-3m | 0.70 |
| 2026-09-19 | Teva real-world data demonstrates UZEDY reduces emergency care and medical costs | Bullish | 3-12m | 0.70 |
| 2026-09-19 | Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity | Bullish | 1-3m | 0.80 |
| 2026-09-19 | Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions | Bullish | 3-12m | 0.80 |
| 2026-09-19 | Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilization | Bullish | 1-3m | 0.80 |
| 2026-09-19 | Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables | Bullish | 1-3m | 0.80 |
| 2026-09-16 | NRx Pharmaceuticals Reports FDA Reclassification of Ketamine Amendment to Minor Amendment | watch | 3-12m | 0.20 |
| 2026-09-07 | Teva launches EUR and USD senior notes to refinance high-coupon 2028-2029 debt | Bullish | 1-3m | 0.70 |
| 2026-09-07 | Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 Debt | Bullish | 1-3m | 0.70 |
| 2026-09-07 | Teva Launches Multi-Currency Senior Notes to Refinance High-Coupon 2028-2029 Debt | Bullish | 1-3m | 0.80 |
| 2026-08-26 | Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms | watch | 3-12m | 0.40 |